Tris Pharma, Inc. Announces Availability of the MyKidz(R) Iron Product Line - the Best Tasting Iron Supplements

MONMOUTH JUNCTION, N.J., March 29, 2011 /PRNewswire/ -- Tris Pharma, Inc., a specialty pharmaceutical company, announced today the highly anticipated re-launch of the MyKidz® Ironproduct line. Since the 2007 launch of MyKidz Iron, it has attracted a loyal following of pediatricians, pediatric nurses and mothers. When the previous marketer decided to focus its product pipeline in a different direction, availability of MyKidz Iron became limited, but the need for a great tasting iron supplement remained. Tris Pharma is stepping-in to provide continuity of care, broader distribution, and ensure that the nutritional needs of infants and toddlers do not go unanswered.

MyKidz Ironproducts are a line of iron supplements without the strong metallic taste common to other marketed iron supplements. MyKidz Iron products are based on a patent-pending, taste-neutral formula where the bad-tasting iron is complexed in a polymeric matrix. The formula further contains a berry/banana fruit flavor that makes it a pleasant tasting supplement which helps to increase compliance. Dr. Louis Reed, a Texas based Pediatrician who has always recommended these supplements, said, "I like MyKidz Iron products because they are the only iron supplements that don't taste like rusty nails, so kids will actually take them." Additionally, these supplements contain no artificial dyes, alcohol or sugars and the special formula helps to reduce the staining of teeth associated with iron.

Iron deficiency is a common problem among children, but it is frequently not detected, and it has long-term health implications for children. It can lead to anemia and/or irreversible effects on children's cognitive and behavioral development. Studies have shown that 4 percent of 6 month olds and 12 percent of 12 month olds tend to be iron deficient. Children between the ages of 1-3 years of age have rates of iron deficiency between 6-15 percent. Pre-term infants, infants who are exclusively breastfed and infants who are at risk for developmental disabilities seem to be at higher risk to develop iron deficiency (1).

"When we received overwhelming feedback," said Ketan Mehta, President and CEO of Tris Pharma, "we realized that there was still a need for a children's iron supplement that was not met by other alternatives. By making these products available again we, at Tris Pharma, expect the MyKidz Iron product line will positively impact the above statistics."

Three formulations are currently available:

  • MyKidz Iron is an iron supplement with vitamins A, C & D, a 2ml dose delivers 10mg of elemental iron plus 1500 IU of Vitamin A, 35mg of Vitamin C and 400 IU of Vitamin D.
  • MyKidz Iron 10 is a high dose iron only, a 1.5 ml dose delivers 15mg of elemental iron.
  • MyKidz Iron FL is a prescription iron supplement with vitamins A, C & D, plus fluoride. In addition to the 10mg of elemental iron and above stated vitamin concentrations, it contains .25mg of fluoride per dose for toddlers requiring fluoride supplementation.

Tris Pharma has launched a new website with detailed information about these iron supplements. For more information including full prescribing information, please visit www.mykidziron.com or call toll free (866)697-9283.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of drug delivery technology based products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' research, development, and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, visit www.trispharma.com.

MyKidz is a trademark of Tris Pharma, Inc.

REFERENCE:

1. AAP News Release "AAP OFFERS GUIDANCE TO BOOST IRON LEVELS IN CHILDREN." Website. http://www.aap.org/pressroom/Ironfinal.pdf. October 5, 2010.

© 2011 Tris Pharma, Inc. Monmouth Junction, NJ.

SOURCE Tris Pharma, Inc.

Back to news